大华继显发表研究报告，指翰森制药(03692.HK) 旗下阿美乐(Ameile)有两个新适应症获批，NSCLC适应症于英国获市场批准。另外恒美达(Hengmeida)用于念珠菌病治疗亦获国家药监局签发药品注册证书；公司其他的产品研发进展顺利。
该行有信心阿美乐于2026年销售达到60亿元人民币、未来几年销售80亿元人民币的目标。维持“买入”评级，目标价升至40港元(原本29港元)。(ss/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-06-05 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.